サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1462860

糖尿病性腎症の世界市場規模調査＆予測、薬剤クラス別、流通チャネル別、地域別分析、2023-2030年

Global Diabetic Nephropathy Market Size study & Forecast, by Drug Class, By by Distribution Channel and Regional Analysis, 2023-2030
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 200 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
糖尿病性腎症の世界市場規模調査＆予測、薬剤クラス別、流通チャネル別、地域別分析、2023-2030年
出版日: 2024年04月05日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文 200 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

糖尿病性腎症の世界市場は、2022年に約25億9,000万米ドルと評価され、予測期間2023-2030年には4.3%以上の健全な成長率で成長すると予測されています。

糖尿病性腎症は、糖尿病の一般的な結果として、血糖値の上昇に長期間さらされることによって生じる腎臓の病気です。尿中にタンパク質、特にアルブミンが検出されるタンパク尿の発生が特徴です。糖尿病患者は、この疾患を発症するリスクが高いです。糸球体濾過率の評価は、糖尿病性腎症に関連する腎臓障害の程度を測る重要な指標となります。糖尿病性腎症市場は、糖尿病有病率の上昇や心血管疾患人口の増加などの要因により拡大しています。その結果、糖尿病性腎症の需要は、予測期間2023-2030年の間に国際市場で徐々に増加しています。

糖尿病は多くの場合、長期的な管理が必要な慢性疾患です。糖尿病と長く付き合えば付き合うほど、糖尿病性腎症を含む合併症を発症する可能性が高くなります。この慢性的な性質が、腎臓合併症の診断、治療、管理に対する持続的な需要の一因となっています。国際糖尿病連合によると、2021年には5億3,700万人の成人が糖尿病と診断され、2030年には6億4,300万人、2045年には7億8,300万人に達すると予測されています。糖尿病性腎症市場を牽引するもう一つの重要な要因は、心血管疾患を抱える人口の増加です。肥満、高血圧、脂質異常症は、糖尿病と心血管疾患の重要な危険因子です。心血管疾患の患者数が増加するにつれ、糖尿病性腎症の発症を助長するこれらの共通危険因子にかかりやすくなる人が増える可能性があります。世界保健機関（WHO）によると、心血管系疾患は世界の主要な死因であり、年間1,790万人の命を奪っていると推定されています。さらに、心臓発作と脳卒中がこれらの心血管疾患による死亡の85％を占めています。さらに、糖尿病性腎症に関連する技術の進歩や、糖尿病治療に対する政府の支援的な取り組みが、予測期間中に市場に有利な成長機会をもたらすと予想されています。しかし、糖尿病性腎症に関連する高コストと腎症における標準化の欠如は、2023-2030年の予測期間を通じて全体的な市場成長を阻害すると思われます。

糖尿病性腎症の世界市場調査において考慮した主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカなどです。北米が2022年に市場を独占したのは、同地域で腎臓病に対する認識を高めるための政府や製薬団体の取り組みが活発化しているためです。啓発プログラムは、糖尿病と腎臓病の関連性についての貴重な情報を提供し、個人が健康状態についての情報を求めるよう促すことができます。入手しやすい情報は、人々が自分の健康について十分な情報を得た上で決断を下し、合併症を予防するための積極的な手段を講じることを後押しします。この地域の圧倒的な実績は、糖尿病性腎症の全体的な需要を促進すると予想されます。さらに、アジア太平洋地域は、予測期間中に最も急速に成長すると予想されています。これは、同地域におけるヘルスケア支出の増加などの要因によるものです。ヘルスケア支出の増加は、糖尿病性腎症患者にとって必要な治療、投薬、ヘルスケアサービスへのアクセスを向上させる。これには、進行した糖尿病性腎症患者に対する透析や腎移植へのアクセスも含まれます。

本調査の目的は、近年におけるさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面の両方を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

第2章 糖尿病性腎症の世界市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 産業の進化
    • 調査範囲
  • 調査対象年
  • 通貨換算レート

第3章 糖尿病性腎症の世界市場力学

  • 糖尿病性腎症市場の影響分析（2020-2030年）
    • 市場促進要因
      • 糖尿病有病率の上昇
      • 心血管疾患人口の増加
    • 市場の課題
      • 糖尿病性腎症に関連する高コスト
      • 腎症における標準化の欠如
    • 市場機会
      • 糖尿病性腎症に関連する技術の進歩
      • 糖尿病治療に対する政府の支援策

第4章 糖尿病性腎症の世界市場産業分析

  • ポーターのファイブフォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターのファイブフォース影響分析
  • PEST分析
    • 政治
    • 経済
    • 社会
    • 技術
    • 環境
    • 法律
  • 主な投資機会
  • 主要成功戦略
  • COVID-19影響分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの結論・提言

第5章 糖尿病性腎症の世界市場：薬剤クラス別

  • 市場スナップショット
  • 糖尿病性腎症の世界市場：薬剤クラス別、実績 - ポテンシャル分析
  • 糖尿病性腎症の世界市場：薬剤クラス別推定・予測 2020-2030年
  • 糖尿病性腎症市場、サブセグメント分析
    • アンジオテンシン変換酵素（ACE）阻害薬
    • アンジオテンシン受容体遮断薬
    • ナトリウムグルコース共輸送体2（SGLT2）阻害薬
    • ミネラルコルチコイド受容体拮抗薬
    • その他

第6章 糖尿病性腎症の世界市場：流通チャネル別

  • 市場スナップショット
  • 糖尿病性腎症の世界市場：流通チャネル別、実績 - ポテンシャル分析
  • 糖尿病性腎症の世界市場：流通チャネル別推定・予測2020-2030年
  • 糖尿病性腎症市場のサブセグメント分析
    • 病院薬局
    • ドラッグストアおよび小売薬局
    • オンライン薬局

第7章 糖尿病性腎症の世界市場：地域別分析

  • 主要国
  • 主な新興国
  • 糖尿病性腎症市場、地域別市場スナップショット
  • 北米
    • 米国
      • 薬剤クラス別推定・予測、2020-2030年
      • 流通チャネル別の推定・予測、2020-2030年
    • カナダ
  • 欧州糖尿病性腎症市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋糖尿病性腎症市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカ糖尿病性腎症市場スナップショット
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • その他中東とアフリカ

第8章 競合情報

  • 主要企業のSWOT分析
  • 主要市場戦略
  • 企業プロファイル
    • Janssen Pharmaceuticals, Inc
      • 主要情報
      • 概要
      • 財務情報（データの入手が可能な場合のみ）
      • 製品概要
      • 最近の動向
    • AstraZeneca plc
    • Aurobindo Pharma Limited
    • Teva Pharmaceutical Industries Ltd
    • Sanofi S.A.
    • Novartis AG
    • Sun Pharmaceutical Industries Ltd
    • Bayer AG
    • Par Pharmaceuticals Inc
    • F. Hoffmann-La Roche Ltd

第9章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • 検証
    • 出版
  • 調査属性
  • 調査前提条件
図表

LIST OF TABLES

  • TABLE 1.Global Diabetic Nephropathy Market, report scope
  • TABLE 2.Global Diabetic Nephropathy Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3.Global Diabetic Nephropathy Market estimates & forecasts by Drug Class 2020-2030 (USD Billion)
  • TABLE 4.Global Diabetic Nephropathy Market estimates & forecasts by Distribution Channel 2020-2030 (USD Billion)
  • TABLE 5.Global Diabetic Nephropathy Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 6.Global Diabetic Nephropathy Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7.Global Diabetic Nephropathy Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8.Global Diabetic Nephropathy Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9.Global Diabetic Nephropathy Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10.Global Diabetic Nephropathy Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11.Global Diabetic Nephropathy Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12.Global Diabetic Nephropathy Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13.Global Diabetic Nephropathy Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14.Global Diabetic Nephropathy Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15.U.S. Diabetic Nephropathy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16.U.S. Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 17.U.S. Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 18.Canada Diabetic Nephropathy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 19.Canada Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 20.Canada Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 21.UK Diabetic Nephropathy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 22.UK Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 23.UK Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 24.Germany Diabetic Nephropathy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 25.Germany Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 26.Germany Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 27.France Diabetic Nephropathy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 28.France Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 29.France Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 30.Italy Diabetic Nephropathy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 31.Italy Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 32.Italy Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 33.Spain Diabetic Nephropathy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 34.Spain Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 35.Spain Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 36.RoE Diabetic Nephropathy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 37.RoE Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 38.RoE Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 39.China Diabetic Nephropathy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 40.China Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 41.China Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 42.India Diabetic Nephropathy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 43.India Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 44.India Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 45.Japan Diabetic Nephropathy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 46.Japan Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 47.Japan Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 48.South Korea Diabetic Nephropathy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 49.South Korea Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 50.South Korea Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 51.Australia Diabetic Nephropathy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 52.Australia Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 53.Australia Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 54.RoAPAC Diabetic Nephropathy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 55.RoAPAC Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 56.RoAPAC Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 57.Brazil Diabetic Nephropathy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 58.Brazil Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 59.Brazil Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 60.Mexico Diabetic Nephropathy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 61.Mexico Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 62.Mexico Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 63.RoLA Diabetic Nephropathy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 64.RoLA Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 65.RoLA Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 66.Saudi Arabia Diabetic Nephropathy Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 67.South Africa Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 68.RoMEA Diabetic Nephropathy Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 69.List of secondary sources, used in the study of global Diabetic Nephropathy Market
  • TABLE 70.List of primary sources, used in the study of global Diabetic Nephropathy Market
  • TABLE 71.Years considered for the study
  • TABLE 72.Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

  • FIG 1.Global Diabetic Nephropathy Market, research methodology
  • FIG 2.Global Diabetic Nephropathy Market, Market estimation techniques
  • FIG 3.Global Market size estimates & forecast methods
  • FIG 4.Global Diabetic Nephropathy Market, key trends 2022
  • FIG 5.Global Diabetic Nephropathy Market, growth prospects 2023-2030
  • FIG 6.Global Diabetic Nephropathy Market, porters 5 force model
  • FIG 7.Global Diabetic Nephropathy Market, pest analysis
  • FIG 8.Global Diabetic Nephropathy Market, value chain analysis
  • FIG 9.Global Diabetic Nephropathy Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10.Global Diabetic Nephropathy Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11.Global Diabetic Nephropathy Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12.Global Diabetic Nephropathy Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13.Global Diabetic Nephropathy Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14.Global Diabetic Nephropathy Market, regional snapshot 2020 & 2030
  • FIG 15.North America Diabetic Nephropathy Market 2020 & 2030 (USD Billion)
  • FIG 16.Europe Diabetic Nephropathy Market 2020 & 2030 (USD Billion)
  • FIG 17.Asia pacific Diabetic Nephropathy Market 2020 & 2030 (USD Billion)
  • FIG 18.Latin America Diabetic Nephropathy Market 2020 & 2030 (USD Billion)
  • FIG 19.Middle East & Africa Diabetic Nephropathy Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global Diabetic Nephropathy Market is valued at approximately USD 2.59 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 4.3% over the forecast period 2023-2030. Diabetic Nephropathy is a kidney ailment resulting from prolonged exposure to elevated blood sugar levels, a common consequence of diabetes. It is characterized by the occurrence of proteinuria, where proteins, notably albumin, are detected in the urine. Diabetic individuals face an increased risk of developing this condition. The assessment of glomerular filtration rate serves as a crucial measure to gauge the extent of kidney impairment associated with diabetic nephropathy. The Diabetic Nephropathy market Market is expanding because of factors such as the rise in the prevalence of diabetes and the growing population with cardiovascular diseases. As a result, the demand of for Diabetic Nephropathy has progressively increased in the international market during the forecast period 2023-2030.

Diabetes is often a chronic condition that requires long-term management. The longer individuals live with diabetes, the higher the likelihood of developing complications, including diabetic nephropathy. This chronic nature contributes to a sustained demand for diagnosis, treatment, and management of kidney complications. According to the International Diabetes Federation, in 2021, 537 million adults were diagnosed with diabetes and projected to reach up to 643 million in number by 2030 and 783 million adults by the year 2045. Another important factor that drives the Diabetic Nephropathy market Market is the growing population with cardiovascular diseases. Obesity, hypertension, and dyslipidemia are important risk factors for both diabetes and cardiovascular disease. Since the number of people with cardiovascular diseases grows, the possibility of that more people to will be susceptible to these common risk factors, which can contribute to the development of diabetic nephropathy. According to the World Health Organization (WHO), it was estimated that cardiovascular diseases are recorded as the leading cause of death around the world, which takes an estimated 17.9 million lives annually. Additionally, heart attacks and strokes account for 85% of these cardiovascular disease deaths. Moreover, technological advancements associated with diabetic nephropathy and supportive government initiatives towards the treatment of diabetes is are anticipated to create a lucrative growth opportunity opportunities for the market over the forecast period. However, the high cost associated with diabetic nephropathy and lack of standardization in nephropathy is going to impede overall market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Diabetic Nephropathy Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising government and pharmaceutical organization efforts to raise awareness of kidney disease in the region. Awareness programs can provide valuable information about the link between diabetes and kidney disease, encouraging individuals to seek information about their health conditions. Accessible information empowers people to make informed decisions about their health and take proactive steps to prevent complications. The region's dominant performance is anticipated to propel the overall demand of for Diabetic Nephropathy. Furthermore, Asia Pacific is expected to grow fastest during over the forecast period, owing to factors such as increased healthcare spending in the region. Increased healthcare spending can improve access to necessary medical treatments, medications, and healthcare services for individuals with Diabetic Nephropathy. This includes access to dialysis or kidney transplantation for those in advanced stages of the disease.

Major market player included in this report are:

  • Janssen Pharmaceuticals, Inc
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Teva Pharmaceutical Industries Ltd
  • Sanofi S.A.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Bayer AG
  • Par Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd

Recent Developments in the Market:

  • In January 2024, Neuralace Medical, Inc., a pain management technology inventor has announced its innovative product, Axon Therapy (mPNS), which has been cleared by the FDA for the treatment of persistent Painful Diabetic Neuropathy (PDN). This approval is the first time the FDA has cleared a non-invasive, magnetic peripheral nerve stimulation (mPNS) treatment for Painful Diabetic Neuropathy.

Global Diabetic Nephropathy Market Report Scope:

  • Historical Data - 2020 - 2021
  • Base Year for Estimation - 2022
  • Forecast period - 2023-2030
  • Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered - Drug Class, Distribution Channel, Region
  • Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class

  • Angiotensin Converting Enzyme (ACE) Inhibitors
  • Angiotensin Receptor Blockers
  • Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
  • Mineralocorticoid Receptor Antagonists
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1.Executive Summary

  • 1.1.Market Snapshot
  • 1.2.Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1.Diabetic Nephropathy Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2.Diabetic Nephropathy Market, by Drug Class, 2020-2030 (USD Billion)
    • 1.2.3.Diabetic Nephropathy Market, by Distribution Channel, 2020-2030 (USD Billion)
  • 1.3.Key Trends
  • 1.4.Estimation Methodology
  • 1.5.Research Assumption

Chapter 2.Global Diabetic Nephropathy Market Definition and Scope

  • 2.1.Objective of the Study
  • 2.2.Market Definition & Scope
    • 2.2.1.Industry Evolution
    • 2.2.2.Scope of the Study
  • 2.3.Years Considered for the Study
  • 2.4.Currency Conversion Rates

Chapter 3.Global Diabetic Nephropathy Market Dynamics

  • 3.1.Diabetic Nephropathy Market Impact Analysis (2020-2030)
    • 3.1.1.Market Drivers
      • 3.1.1.1.Rise in prevalence of diabetes
      • 3.1.1.2.Growing population with cardiovascular diseases.
    • 3.1.2.Market Challenges
      • 3.1.2.1.High cost associated with diabetic nephropathy.
      • 3.1.2.2.Lack of standardization in nephropathy.
    • 3.1.3.Market Opportunities
      • 3.1.3.1.Technological advancements associated with diabetic nephropathy.
      • 3.1.3.2.Supportive government initiatives towards treatment of diabetes

Chapter 4.Global Diabetic Nephropathy Market Industry Analysis

  • 4.1.Porter's 5 Force Model
    • 4.1.1.Bargaining Power of Suppliers
    • 4.1.2.Bargaining Power of Buyers
    • 4.1.3.Threat of New Entrants
    • 4.1.4.Threat of Substitutes
    • 4.1.5.Competitive Rivalry
  • 4.2.Porter's 5 Force Impact Analysis
  • 4.3.PEST Analysis
    • 4.3.1.Political
    • 4.3.2.Economical
    • 4.3.3.Social
    • 4.3.4.Technological
    • 4.3.5.Environmental
    • 4.3.6.Legal
  • 4.4.Top investment opportunity
  • 4.5.Top winning strategies
  • 4.6.COVID-19 Impact Analysis
  • 4.7.Disruptive Trends
  • 4.8.Industry Expert Perspective
  • 4.9.Analyst Recommendation & Conclusion

Chapter 5.Global Diabetic Nephropathy Market, by Drug Class

  • 5.1.Market Snapshot
  • 5.2.Global Diabetic Nephropathy Market by Drug Class, Performance - Potential Analysis
  • 5.3.Global Diabetic Nephropathy Market Estimates & Forecasts by Drug Class 2020-2030 (USD Billion)
  • 5.4.Diabetic Nephropathy Market, Sub Segment Analysis
    • 5.4.1.Angiotensin Converting Enzyme (ACE) Inhibitors
    • 5.4.2.Angiotensin Receptor Blockers
    • 5.4.3.Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
    • 5.4.4.Mineralocorticoid Receptor Antagonists
    • 5.4.5.Others

Chapter 6.Global Diabetic Nephropathy Market, by Distribution Channel

  • 6.1.Market Snapshot
  • 6.2.Global Diabetic Nephropathy Market by Distribution Channel, Performance - Potential Analysis
  • 6.3.Global Diabetic Nephropathy Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
  • 6.4.Diabetic Nephropathy Market, Sub Segment Analysis
    • 6.4.1.Hospital Pharmacies
    • 6.4.2.Drug Stores & Retail Pharmacies
    • 6.4.3.Online Pharmacies

Chapter 7.Global Diabetic Nephropathy Market, Regional Analysis

  • 7.1.Top Leading Countries
  • 7.2.Top Emerging Countries
  • 7.3.Diabetic Nephropathy Market, Regional Market Snapshot
  • 7.4.North America Diabetic Nephropathy Market
    • 7.4.1.U.S. Diabetic Nephropathy Market
      • 7.4.1.1.Drug Class breakdown estimates & forecasts, 2020-2030
      • 7.4.1.2.Distribution Channel breakdown estimates & forecasts, 2020-2030
    • 7.4.2.Canada Diabetic Nephropathy Market
  • 7.5.Europe Diabetic Nephropathy Market Snapshot
    • 7.5.1.U.K. Diabetic Nephropathy Market
    • 7.5.2.Germany Diabetic Nephropathy Market
    • 7.5.3.France Diabetic Nephropathy Market
    • 7.5.4.Spain Diabetic Nephropathy Market
    • 7.5.5.Italy Diabetic Nephropathy Market
    • 7.5.6.Rest of Europe Diabetic Nephropathy Market
  • 7.6.Asia-Pacific Diabetic Nephropathy Market Snapshot
    • 7.6.1.China Diabetic Nephropathy Market
    • 7.6.2.India Diabetic Nephropathy Market
    • 7.6.3.Japan Diabetic Nephropathy Market
    • 7.6.4.Australia Diabetic Nephropathy Market
    • 7.6.5.South Korea Diabetic Nephropathy Market
    • 7.6.6.Rest of Asia Pacific Diabetic Nephropathy Market
  • 7.7.Latin America Diabetic Nephropathy Market Snapshot
    • 7.7.1.Brazil Diabetic Nephropathy Market
    • 7.7.2.Mexico Diabetic Nephropathy Market
  • 7.8.Middle East & Africa Diabetic Nephropathy Market
    • 7.8.1.Saudi Arabia Diabetic Nephropathy Market
    • 7.8.2.South Africa Diabetic Nephropathy Market
    • 7.8.3.Rest of Middle East & Africa Diabetic Nephropathy Market

Chapter 8.Competitive Intelligence

  • 8.1.Key Company SWOT Analysis
  • 8.2.Top Market Strategies
  • 8.3.Company Profiles
    • 8.3.1.Janssen Pharmaceuticals, Inc
      • 8.3.1.1.Key Information
      • 8.3.1.2.Overview
      • 8.3.1.3.Financial (Subject to Data Availability)
      • 8.3.1.4.Product Summary
      • 8.3.1.5.Recent Developments
    • 8.3.2.AstraZeneca plc
    • 8.3.3.Aurobindo Pharma Limited
    • 8.3.4.Teva Pharmaceutical Industries Ltd
    • 8.3.5.Sanofi S.A.
    • 8.3.6.Novartis AG
    • 8.3.7.Sun Pharmaceutical Industries Ltd
    • 8.3.8.Bayer AG
    • 8.3.9.Par Pharmaceuticals Inc
    • 8.3.10.F. Hoffmann-La Roche Ltd

Chapter 9.Research Process

  • 9.1.Research Process
    • 9.1.1.Data Mining
    • 9.1.2.Analysis
    • 9.1.3.Market Estimation
    • 9.1.4.Validation
    • 9.1.5.Publishing
  • 9.2.Research Attributes
  • 9.3.Research Assumption